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Abstract 
Background: Cold atmospheric plasma could constitute an alternative against multi-drug resistant pathogens. Sus-
ceptibility of enterococci to cold atmospheric plasma was investigated in vitro.
Methods: 39 clinical isolates of enterococci were grouped dependent on the most important resistance patterns 
and treated on agar using dielectric barrier discharge plasma. These included enterococci with combined vancomy-
cin- and high-level gentamicin resistance, high-level resistance to gentamicin (HLGR) only, vancomycin resistance 
alone (VRE), and enterococci susceptible to both. Susceptibility to cold atmospheric plasma was evaluated based on 
the zones of inhibition and examined in terms of the enterococcal group and the “degree” of drug resistance.
Results: Cold atmospheric plasma treatment killed all groups. Comparison of VRE and HLGR strains with non-VRE and 
non-HLGR isolates concerning zones of inhibition revealed that enterococci with special resistance patterns (VRE and 
HLGR) showed significantly smaller zones of inhibition than the sensitive ones. The mean of all isolates, irrespective of 
belonging to groups, showed smaller zones of inhibition with increasing “degree” of drug resistance.
Conclusions: Cold atmospheric plasma treatment killed all isolates of enterococci, but its efficacy depended on the 
“degree” of drug resistance and on membership in special resistance groups with particular clinical-outbreak impor-
tance. However, a possible role of the different genetic lineages, which might be prone to acquiring more or less 
resistance phenotypes, may also play a role in this context.
Keywords: Dielectric barrier discharge plasma (DBD), Cold atmospheric plasma (CAP), Antimicrobial efficacy, Plasma 
susceptibility, Plasma medicine, Vancomycin-resistant enterococci, Gentamicin-resistant enterococci
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Background
The microorganisms most often involved in multi-drug 
(MDR) resistance are the so-called ESKAPE pathogens 
(Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa, and enterobacteriaceae except Klebsiella), 
suggesting their proclivity in escaping antibacterial 
treatments [1, 2]. Beyond the search for new antibi-
otic drugs, novel antimicrobial strategies as alternatives 
to conventional agents with antimicrobial efficacy are 
strongly needed [3]. One new concept is cold atmos-
pheric plasma (CAP), which combines potent physi-
cal properties such as ultraviolet and infrared radiation 
(within the near infrared region), reactive oxidative spe-
cies, and charged particles [4–7]. In previous studies, 
the present authors showed significant efficacy of CAP 
in  vitro against bacterial and fungal species [5, 8]. Suc-
cessful treatments of different infectious diseases based 
on the considerable antimicrobial efficacy of CAP have 
been documented; hence, it can be deduced that plasma 
could be effective in hospital hygiene and wound medi-
cine, as chronic wounds represent an important risk fac-
tor for MDR colonization [9–16].
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However, to fulfil aforementioned high expectations in 
CAP as innovative alternative in the treatment of MDR 
pathogens, CAP efficacy should not be affected by resist-
ance to antibiotics.
Therefore, two factors possibly influencing plasma 
susceptibility of enterococci were investigated: first, the 
“degree” of multi-drug resistance of enterococci, and sec-
ond, the role of pathogens known as outbreak strains—the 
vancomycin-resistant enterococci (VRE) and/or entero-
cocci resistant to high doses of gentamicin (HLGR).
Methods
The aim of this in vitro-study was to determine the sus-
ceptibility of clinical isolates of enterococci showing 
different patterns of antimicrobial resistance to CAP 
treatment.
Plasma source
The plasma source used was a dielectric barrier discharge 
(DBD) plasma device with a high voltage electrode of 
20  mm in diameter developed by the CINOGY GmbH, 
Duderstadt, Germany. The electrode is being covered 
with a dielectric barrier made of an industrial ceramic. 
The pulse repetition rate of the device was adjusted on 
250 Hz which leads to electric power dissipated in the gas 
discharge within the range of 167–237 mW [17]. The area 
covered by the visible plasma beam averaged 314 mm2.
Susceptibility test model in vitro
CAP susceptibility was calculated as described detailed 
in a previous publication [5]. In few words, before start-
ing plasma treatment, the strains were thawed and cul-
tured aerobically at 36 °C overnight on sheep blood agar 
(Columbia agar, Biomérieux, Nürtingen, Germany). 
Suspensions were made out of these overnight cultures, 
diluted in sterile saline (1 colony in 1  ml). This suspen-
sion was diluted 1/100 in sterile saline (optical density 
was proved by measurement of McFarland) and 100  ml 
were plated on Columbia blood agar under sterile condi-
tions. All isolates of enterococci were treated for 3  s by 
CAP on agar. Treatments were done under controlled 
room climate with temperatures not surpassing 21  °C 
and a humidity of ca. 45 %.
To compute the CAP susceptibility, the diameters 
(mean of two measurements at a 90° angle) of the 
obtained circular zones of inhibition (ZOI) were meas-
ured and the area calculated.
Microbiology
A total of 39 clinical isolates were included, 16 E. faecium 
and 23 Enterococcus faecalis. Isolates were recovered 
consecutively during routine wound microbiology at the 
University Hospital of Greifswald, Germany. VRE identi-
fied as outbreak strains and isolated elsewhere were pro-
vided by the National Reference Center for Staphylococci 
and Enterococci, Robert Koch Institute, Wernigerode, 
Germany [18].
The different isolates were grouped according to their 
resistance pattern, including sensitive, vancomycin resist-
ance (VRE) and high level gentamycin resistance (HLGR) 
as seen in Table 1 (membership of one isolate in several 
groups was possible).
Irrespective of above-mentioned resistance patterns 
were all 39 isolates differentiated into subgroups depend-
ing on their “degree” of antimicrobial resistance (resist-
ance group, RG), due to the automated break-point 
determination test (breakpoints based on DIN and CA-
SFM as interpretation criteria) in the VITEK® 2 Com-
pact System (bioMérieux, Nürtigen, Germany). The 12 
classes of antibiotic agents tested are given in Fig. 1 with 
the corresponding percentage of isolates showing resist-
ance. The maximum number of resistances of one isolate 
in this study was 10, meaning that this isolate was placed 
in RG10.
Statistical analysis
A paired t test with a significance level of 5  % was 
applied to compare the species-specific (groups 1–6) 
ZOI obtained after plasma treatment. Furthermore, an 
analysis of variance was performed to test for signifi-
cant differences related to the “degree” of resistance (RG 
2–10). For all calculations, the free software package R 
Table 1 Total number (n) of isolates and number of specific species within the different groups
a Group 3: containing all HLGR strains, group 5: containing all VRE strains
b Enterococci with susceptibility to vancomycin and high concentrations of gentamicin
Group 1 other entero-
cocci (oE)b
Group 2 HLGR only Group 3a group 
2 + 4
Group 4 VRE 
and HLGR
Group 5a group 
6 + 4
Group 6 VRE 
only
n of isolates 12 11 19 8 16 8
E. faecium 1 5 9 4 10 6
E. faecalis 11 6 10 4 6 2
Page 3 of 7Napp et al. Gut Pathog  (2016) 8:41 
(R Development Core Team, R Foundation for Statistical 
Computing, Vienna, Austria) was used.
Results
In all enterococci isolates plasma treatment resulted in 
circular bacteria-free areas (ZOI) in the homogeneous 
growth zone of the agar surface within 48 h.
The ZOI of the enterococcal groups 1–6 are presented 
in Fig.  2. The group of “other enterococci” (group 1) 
showed the biggest ZOI (486 mm2). The VRE (group 6) 
exhibited the smallest ZOI (290  mm2). The difference 
between the maximum (oE, group 1) and minimum 
ZOI (only VRE, group 6) measured 178.4 mm2, equal to 
38.1  %. Additionally, E. faecium exhibited higher CAP 
resistance than E. faecalis.
The comparison of groups and pooled groups of ente-
rococcal isolates with different antimicrobial resistance 
patterns (i.e. VRE, HLGR, etc.) revealed significant dif-
ferences in sizes of ZOI (Table  2). Significantly smaller 
ZOI were found in VRE strains (group 5) as well as in 
HLGR isolates (group 3) compared with non-VRE and 
non-HLGR isolates, respectively. As shown by the sig-
nificantly larger ZOI in group 1 compared with all other 
groups, the highest CAP efficacy was obtained in the 
group of enterococci without the clinically important 
resistance patterns (group 1).
The statistical analysis of single isolates regarding the 
“degree” of drug resistance revealed that isolates with 
superior RG numbers showed smaller ZOI (p  =  0.045) 
than isolates with lower RG numbers (Fig. 3). These find-
ings did not occur within the statistical analysis of the 
enterococcal (resistance pattern) groups, probably due 
to the very small numbers within the different groups 
(Fig. 4a–f).
Discussion
Clinically relevant enterococci primarily include two spe-
cies, E. faecalis and E. faecium. Both species exhibit high 
levels of resistance against the aminoglycosides, and E. 
faecium is inherently resistant to β-lactam antibiotics. 
Currently, most isolates of E. faecium are highly resistant 
to ampicillin, while a non-negligible proportion exhibit 
high-level resistance to aminoglycosides and are resistant 
to glycopeptides, causing outbreaks in clinical settings 
[19].
Additionally, an increasing resistance to the newer anti-
microbials linezolid, daptomycin and tigecycline could be 
observed in many countries [20].
Fig. 1 Number (n) of isolates showing resistance to the respective class of antibiotics and related percentage
Page 4 of 7Napp et al. Gut Pathog  (2016) 8:41 
Few studies have been published on plasma suscep-
tibility of multidrug-resistant strains (e.g. VRE), such as 
those referring to decontamination of surfaces in hospi-
tal environments [21, 22]. However, no data on entero-
cocci in terms of antibiotic resistance are available. From 
previous studies focussing on basic plasma suitability for 
inactivating wound and skin bacteria [8, 20, 23], no sta-
tistically supported conclusions on enterococcal suscep-
tibility to plasma treatment can be drawn. Therefore, the 
antimicrobial efficacy of plasma from a well-researched 
plasma source (DBD) against a set of clinical isolates of 
enterococci, including VRE and HLGR, was investigated 
in vitro.
It was clearly demonstrated that the DBD easily elimi-
nated all isolates of enterococci examined here, regard-
less of special resistance patterns such as VRE and 
HLGR. Interestingly, significant differences were found 
when the obtained ZOI diameters of distinct groups were 
compared.
The most obvious finding was that E. faecium was 
more resistant to plasma treatment than E. faecalis, 
which resembles the well-known greater drug suscepti-
bility of E. faecalis compared to that of E. faecium. The 
reasons for the difference in plasma susceptibility of 
these two species could not get cleared in this study as 
the number of isolates did not allow deeper statistical 
analysis. Nevertheless, this result could be the next hint 
to related resistance mechanisms to CAP and antibiotics 
in enterococci.
The next important observation is that the authors 
found lower CAP susceptibility of VRE and HLGR 
treated with DBD in comparison with enterococci lack-
ing these clinically important resistance patterns.
Fig. 2 Mean (ranked) zone of inhibition (ZOI) (mm2 with SD) on agar obtained after treatment with DBD, total and by group
Table 2 Significant differences (p value) in  ZOI 
between the different enterococcal groups
Compared groups Mean (SD) ZOI (mm2) 
of respective group
p value
Group 1 vs. 2 468.1 (71.6) vs. 334.4 (69.1) 0.000
Group 1 vs. 4 468.1 (71.6) vs. 301.0 (44.8) 0.000
Group 4 vs. 6 301.0 (44.8) vs. 289.7 (42) 0.000
Group 1 vs. all other isolates 468.1 (71.6) vs. 311.3 (56.0) 0.000
Group 3 vs. all other isolates 320.3 (61.0) vs. 396.8 (105.3) 0.017
Group 4 vs. all other isolates 301.0 (44.8) vs. 374.6 (97.7) 0.014
Group 5 vs. all other isolates 295.4 (42.4) vs. 404.2 (94.8) 0.000
Group 6 vs. all other isolates 289.7 (42.0) vs. 377.6 (95.7) 0.002
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In addition, “higher” resistance to chemical antibiotics 
was correlated with less susceptibility to DBD (decrease 
in killing-zone diameter). This correlation was found only 
for all isolates irrespective of belonging to specific resist-
ance groups probably due to the very small numbers 
within the different groups.
Based on the overall results, an influence of vanco-
mycin resistance and HLGR on CAP susceptibility can 
be assumed for DBD, since the properties “vancomycin 
resistance” and “HLGR alone” confer significantly smaller 
ZOI on agar. However, a possible influence of the differ-
ent genetic lineages, which might be prone of acquiring 
more or less resistant phenotypes, may also play a role in 
this context.
Although the data presented here strongly indi-
cate plasma susceptibility of all enterococci, the lower 
Fig. 3 Mean (SD) ZOI (mm2) on agar obtained after treatment with DBD and respective resistance group (RG) of all enterococci
Fig. 4 a- f Mean (SD) ZOI (mm2) on agar obtained after treatment with DBD and respective resistance group (RG) shown separately for group 1 (a), 
2 (b), 3 (c), 4 (d), 5 (e) and 6 (f)
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susceptibility of E. faecium (compared to E. faecalis), 
VRE, HLGR, and generally MDR enterococci against 
DBD suggest the need for further research to clarify the 
as-yet unknown mechanisms by which bacteria are killed 
by CAP. This phenomenon could also help recognize and 
manage potential bacterial resistance mechanisms, which 
have not yet been documented.
Conclusion
Plasma treatment with DBD was followed by a signifi-
cant reduction of all tested enterococci, irrespective of 
species and antibiotic resistance pattern. However, the 
obtained data indicate significantly less susceptibility of 
VRE and HLGR enterococci as well as less susceptibility 
of E. faecium to CAP derived from a DBD source and a 
correlation between decreasing susceptibility to CAP 
and increasing resistance level of enterococci (Additional 
file 1).
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